CSF2 and myalgic encephalomeyelitis/chronic fatigue syndrome: Since patients with chronic fatigue syndrome have lower GM-CSF levels in cerebrospinal fluid [45], these results suggest that this cytokine could be an important mediator of “fatigue-like” effects in preclinical models.